Mostrando 8 resultados de: 8
Filtros aplicados
Publisher
International Journal of Molecular Sciences(2)
Advances in Pharmacological Sciences(1)
Current Diabetes Reviews(1)
F1000Research(1)
Journal of Diabetes Research(1)
Área temáticas
Enfermedades(7)
Farmacología y terapéutica(3)
Medicina y salud(2)
Medicina forense; incidencia de enfermedades(1)
Salud y seguridad personal(1)
Clinical-epidemiological analysis of hdl2 and hdl3 subfractions in adults from maracaibo city, venezuela
ArticleAbstract: Objective: To carry out a clinical-epidemiological analysis of high-density lipoprotein cholesterolPalabras claves:Cholesterol, HDL, Epidemiology (source: MeSH NLM), Lipoproteins, HDL2, Lipoproteins, HDL3, RISK FACTORSAutores:Alex Patricio Morales-Carrasco, Calvo M.J., González M.C., Linares S., Martínez M.S., Nava M., Olivar L.C., Ortega A., Rojas-Quintero J., Salazar-Vílchez J., Valmore BermúdezFuentes:scopusDepression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines
ReviewAbstract: Depression is currently recognized as a crucial problem in everyday clinical practice, in light of ePalabras claves:Autores:Chávez-Castillo M., Nava M., Nuñez V., Ortega A., Rojas M., Rojas-Quintero J., Valmore BermúdezFuentes:scopusNon-HDL cholesterol is better than ldl-c at pbkp_redicting atherosclerotic cardiovascular disease risk factors clustering, even in subjects with near-to-normal triglycerides: A report from a venezuelan population
ArticleAbstract: Background: Non-high density lipoprotein cholesterol (non-HDL-c) has emerged as an important tool inPalabras claves:ASCVD, cholesterol, Coronary artery disease, LDL-c, Non-HDL-c, risk factorAutores:de Bravo M.C., D’Addosio R., Graterol M., Graterol R., Hoedebecke K., Lameda V., Martínez M.S., Olivar L.C., Ortega A., Ramírez P., Rastogi S., Rojas E.R., Rojas M., Rojas-Quintero J., Salazar-Vílchez J., Torres W., Valmore Bermúdez, Wilches S.Fuentes:scopusLipid Accumulation Product Is More Related to Insulin Resistance than the Visceral Adiposity Index in the Maracaibo City Population, Venezuela
ArticleAbstract: Background. Visceral adiposity is related to insulin resistance (IR), a metabolic state considered aPalabras claves:Autores:Añez-Ramos R., Cano-Ponce C., Dávila L.C.A., Durán P., Fuenmayor J., González M.C., Nava M., Ortega A., Rivas-Montenegro A., Rojas M., Rojas-Quintero J., Salazar-Vílchez J., Valmore Bermúdez, Velasco M.Fuentes:scopusIs “leptin resistance” another key resistance to manage type 2 diabetes?
ReviewAbstract: Although novel pharmacological options for the treatment of type 2 diabetes mellitus (DM2) have beenPalabras claves:Adipokines, DIABÉTES, Hyperleptinemia, Insulin Resistance, leptin, Leptin resistance, obesityAutores:Chávez-Castillo M., Cristobal Ignacio Espinoza Díaz, Dávila L.C.A., D’marco L., González M.C., Herazo Y., Nava M., Ortega A., Pérez J.L., Rojas M., Rojas-Gómez D.M., Rojas-Quintero J., Salazar-Vílchez J., Valmore BermúdezFuentes:googlescopusRole of endocrine-disrupting chemicals in the pathogenesis of non-alcoholic fatty liver disease: A comprehensive review
ReviewAbstract: Non-alcoholic fatty liver disease (NAFLD) is considered the most common liver disorder, affecting arPalabras claves:Endocrine-disrupting chemicals, Environmental pollutants, Exposure, Liver disorder, Non-alcoholic fatty liver diseaseAutores:Cano G., Cano R.A., Dávila L.C.A., Diaz M.P., Gomez Y., González M.C., Manzano A., Ortega A., Parra H., Pérez J.L., Rojas-Quintero J., Valero-Cedeño N.J., Valmore Bermúdez, Veliz T.Fuentes:scopusSGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
ReviewAbstract: Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) aPalabras claves:Autores:D’marco L., Morillo V., Nava M., Ortega A., Parra H., Rojas-Quintero J., Suarez M.K., Teruel J.L., Valmore Bermúdez, Villasmil N.Fuentes:scopusPsycho-Neuro-Endocrine-Immunological Basis of the Placebo Effect: Potential Applications beyond Pain Therapy
ReviewAbstract: The placebo effect can be defined as the improvement of symptoms in a patient after the administratiPalabras claves:Analgesia, Cannabinoids, Conditioning, Depression, hormones, Opioid, Pain, Parkinson’s Disease, placebo effect, PsychoneuroimmunologyAutores:Ariza D., Chávez-Castillo M., Díaz-Camargo E.A., Galbán N., Medina-Ortiz O., Nava M., Ortega A., Riaño-Garzón M.E., Rojas M., Salazar-Vílchez J., Valmore BermúdezFuentes:scopus